BiTE® (Bispecific T cell Engager) antibody constructs are a type of fusion protein that is designed to harness the power of the immune system to treat cancer. These bispecific molecules are created by linking the targeting regions of two antibodies. One arm of the molecule is engineered to bind with a protein found on the surface of cytotoxic T cells, and the other arm is designed to bind to a specific protein found primarily on tumor cells.
When both targets are engaged, the BiTE® molecule forms a bridge between the cytotoxic T cell and the tumor cell, which enables the T cell to recognize the tumor cell and fight it through an infusion of toxic molecules. The tumor-binding arm of the molecule can be altered to create different BiTE® antibody constructs that target different types of cancer.